Linopristin/flopristin
| Combination of | |
|---|---|
| Linopristin | antibiotic |
| Flopristin | antibiotic |
| Clinical data | |
| Other names | NXL103; XRP 2868 |
| Identifiers | |
| CAS Number | |
NXL103 (formerly XRP 2868) is an experimental drug candidate under development by Novexel. It is an oral streptogramin antibiotic that has potent in vitro activity against certain Gram positive bacteria including methicillin resistant Staphylococcus aureus (MRSA) as well as the important respiratory pathogens including penicillin-, macrolide- and quinolone-resistant strains.[1][2] It is a combination of linopristin and flopristin.[3]
Clinical trials
Positive results have been reported from a phase II trial comparing it with amoxicillin.[1] Another phase II trial will be run in 2010[needs update] comparing it with linezolid for treatment of acute bacterial skin and skin structure infections (ABSSSI).[4]
References
- ^ a b Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia, drugs.com
- ^ Pankuch, GA; Hoellman, D; Bryskier, A; Lowther, J; Appelbaum, PC (2006). "Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae". Antimicrobial agents and chemotherapy. 50 (11): 3914–6. doi:10.1128/AAC.00587-06. PMC 1635171. PMID 17065630.
- ^ NXL103 at Novexel.com
- ^ Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI), clinicaltrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |